Clinical Trials and Development, American Pathology Partners-UniPath, Denver, CO, USA.
Molecular Biology and Biotechnology Department, Instituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Gran Asunción, Paraguay.
Clin Chem Lab Med. 2020 May 8;59(2):301-306. doi: 10.1515/cclm-2020-0101.
Quality management for clinical laboratories requires the establishment of internal procedures including standard operating procedures (SOPs), internal quality control (QC), validation of test results and quality assessment. External quality assessment (EQA) and alternativeassessment procedures (AAPs) are part of the quality hierarchy required for diagnostic testing. The International Organization for Standardization (ISO) document with requirements for conformance ISO 15189 and the Clinical and Laboratory Standards Institute document (CLSI) QMS24 require participation in EQA schemes and AAPs where applicable. The purpose of this study was to perform a global survey of EQA and AAPs for key procedures in molecular diagnostic laboratories.
The Committee for Molecular Diagnostics of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC C-MD) conducted a survey of international molecular laboratories that covered specific topics of molecular diagnostic services as well as methods for EQA and AAPs. The survey addressed the following aspects: (1) usage of laboratory-developed test (LDT), (2) participation in EQA schemes and (3) performance of AAPs.
A total of 93 responses from laboratories located in Asia, Europe, the Middle East, North America and South America were received. The majority of the participating laboratories (65.9%) use LDTs and 81.3% stated that it is mandatory for them to participate in EQA programs, while 22% of the laboratories reported not performing AAPs. Thirty-one percent of the laboratories use EQAs for fewer than 50.0% of their reported parameters/analytes.
While the majority of laboratories perform EQA and AAPs to improve their quality in molecular diagnostics, the amount of AAPs as quality procedures differs within the laboratories. Further surveys are necessary to clarify the existing needs in additional EQAs and standardized AAPs. The survey will also guide future efforts of the IFCC C-MD for identifying quality practices in need to improve harmonization and standardization within molecular diagnostics.
临床实验室质量管理需要建立内部程序,包括标准操作规程(SOP)、内部质量控制(QC)、检验结果验证和质量评估。室间质量评价(EQA)和替代评估程序(AAP)是诊断检测所需的质量层次结构的一部分。国际标准化组织(ISO)文件中有符合 ISO 15189 要求的文件,临床和实验室标准协会(CLSI)QMS24 文件要求在适用的情况下参与 EQA 计划和 AAP。本研究的目的是对分子诊断实验室关键程序的 EQA 和 AAP 进行全球调查。
国际临床化学和实验室医学联合会(IFCC)分子诊断委员会(C-MD)对国际分子实验室进行了调查,涵盖了分子诊断服务的具体主题以及 EQA 和 AAP 方法。该调查涉及以下方面:(1)实验室自建检测(LDT)的使用,(2)参与 EQA 计划,(3)进行 AAP。
共收到来自亚洲、欧洲、中东、北美和南美实验室的 93 份回复。大多数参与实验室(65.9%)使用 LDT,81.3%表示必须参与 EQAP 计划,而 22%的实验室报告未进行 AAP。31%的实验室使用 EQAs 的比例低于其报告的参数/分析物的 50.0%。
虽然大多数实验室通过执行 EQA 和 AAP 来提高分子诊断的质量,但作为质量程序的 AAP 数量在不同实验室之间存在差异。需要进一步调查以明确额外 EQAs 和标准化 AAP 的现有需求。该调查还将指导 IFCC C-MD 未来努力,以确定需要改进分子诊断内部协调和标准化的质量实践。